ATHA Athira Pharma


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On May 27, 2021, Athira Pharma, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, 24,871,871 shares of the Company’s common stock, or approximately 67% of the total shares entitled to vote, were present virtually or by proxy and voted on the following proposals, which are described in more detail in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission (the “SEC”) on April 16, 2021:

Proposal One – Election of Class I Directors. The following nominees were elected as Class I directors to serve until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified.

NomineeForWithholdBroker Non-Votes
Tadataka Yamada, M.D.16,341,8704,067,0244,462,977
Leen Kawas, Ph.D.17,972,2622,436,6324,462,977
Barbara Kosacz19,961,742447,1524,462,977

Proposal Two – Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2021 was ratified.